These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31929349)

  • 21. Cabozantinib for the treatment of kidney cancer.
    Abdelaziz A; Vaishampayan U
    Expert Rev Anticancer Ther; 2017 Jul; 17(7):577-584. PubMed ID: 28633552
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic Stratification by the Meet-URO Score in Real-World Older Patients With Metastatic Renal Cell Carcinoma (mRCC) Receiving Cabozantinib: A Subanalysis of the Prospective ZEBRA Study (Meet-URO 9).
    Damassi A; Cremante M; Signori A; Rebuzzi SE; Fornarini G; Giudice GC; Maruzzo M; Procopio G; Sorarù M; Di Napoli M; Fratino L; Santini D; Grillone F; Ballestrin M; Dionese M; Nasso C; Catalano F; Murianni V; Rescigno P; Anpalakhan S; Banna GL; Basso U; Buti S
    Clin Genitourin Cancer; 2024 Apr; 22(2):126-133.e2. PubMed ID: 37932204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program.
    Procopio G; Prisciandaro M; Iacovelli R; Cortesi E; Fornarini G; Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E
    Clin Genitourin Cancer; 2018 Aug; 16(4):e945-e951. PubMed ID: 29753637
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma.
    McGregor BA; Lalani AA; Xie W; Steinharter JA; E Bakouny Z; Martini DJ; Fleischer JH; Abou-Alaiwi S; Nassar A; Nuzzo PV; Kaymakcalan MD; Braun DA; Wei XX; Harshman LC; Bilen MA; Choueiri TK
    Eur J Cancer; 2020 Aug; 135():203-210. PubMed ID: 32599410
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cabozantinib for Renal Cell Carcinoma: Current and Future Paradigms.
    Abdelaziz A; Vaishampayan U
    Curr Treat Options Oncol; 2017 Mar; 18(3):18. PubMed ID: 28286925
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world Practice Patterns and Safety of Concurrent Radiotherapy and Cabozantinib in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Loo Gan C; Huang J; Pan E; Xie W; Schmidt AL; Labaki C; Meza L; Bouchard G; Li H; Jackson-Spence F; Sánchez-Ruiz C; Powles T; Kumar SA; Weise N; Hall WA; Rose BS; Beuselinck B; Suarez C; Pal SK; Choueiri TK; Heng DYC; McKay RR
    Eur Urol Oncol; 2023 Apr; 6(2):204-211. PubMed ID: 36328934
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cabozantinib use in renal cell carcinoma.
    Neuwelt AJ; Mathur S; Johnson AT; Kessler ER; Bowles DW
    Drugs Today (Barc); 2017 May; 53(5):299-307. PubMed ID: 28650002
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long progression-free survival with cabozantinib in a heavily pretreated patient with metastatic renal cell carcinoma: a case report.
    Nasso C; Sabbatini R; Baldessari C; Dominici M; Vitale MG
    Tumori; 2021 Dec; 107(6):NP33-NP36. PubMed ID: 33526000
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world evidence of cabozantinib in patients with metastatic renal cell carcinoma: Results from the CABOREAL Early Access Program.
    Albiges L; Fléchon A; Chevreau C; Topart D; Gravis G; Oudard S; Tourani JM; Geoffrois L; Meriaux E; Thiery-Vuillemin A; Barthélémy P; Ladoire S; Laguerre B; Perrot V; Billard A; Escudier B; Gross-Goupil M
    Eur J Cancer; 2021 Jan; 142():102-111. PubMed ID: 33253997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Effect of Concomitant Proton Pump Inhibitor and Cabozantinib on the Outcomes of Patients with Metastatic Renal Cell Carcinoma.
    Rassy E; Cerbone L; Auclin E; Benchimoll-Zouari A; Flippot R; Alves Costa Silva C; Colomba E; Geraud A; Guida A; Mir O; Combarel D; Paci A; Escudier B; Albiges L
    Oncologist; 2021 May; 26(5):389-396. PubMed ID: 33554383
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cabozantinib for the treatment of patients with metastatic non-clear cell renal cell carcinoma: A retrospective analysis.
    Campbell MT; Bilen MA; Shah AY; Lemke E; Jonasch E; Venkatesan AM; Altinmakas E; Duran C; Msaouel P; Tannir NM
    Eur J Cancer; 2018 Nov; 104():188-194. PubMed ID: 30380460
    [TBL] [Abstract][Full Text] [Related]  

  • 32. In brief: Cabozantinib (Cabometyx) for advanced renal cell carcinoma.
    Med Lett Drugs Ther; 2016 Jul; 58(1499):e97. PubMed ID: 27403787
    [No Abstract]   [Full Text] [Related]  

  • 33. Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma: Real-world Data From an Italian Managed Access Program.
    Prisciandaro M; Ratta R; Massari F; Fornarini G; Caponnetto S; Iacovelli R; De Giorgi U; Facchini G; Scagliarini S; Sabbatini R; Caserta C; Peverelli G; Mennitto A; Verzoni E; Procopio G
    Am J Clin Oncol; 2019 Jan; 42(1):42-45. PubMed ID: 30204614
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cabozantinib in Combination with Immunotherapy for Advanced Renal Cell Carcinoma and Urothelial Carcinoma: Rationale and Clinical Evidence.
    Bergerot P; Lamb P; Wang E; Pal SK
    Mol Cancer Ther; 2019 Dec; 18(12):2185-2193. PubMed ID: 31792125
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical Activity and Safety of Cabozantinib for Brain Metastases in Patients With Renal Cell Carcinoma.
    Hirsch L; Martinez Chanza N; Farah S; Xie W; Flippot R; Braun DA; Rathi N; Thouvenin J; Collier KA; Seront E; de Velasco G; Dzimitrowicz H; Beuselinck B; Xu W; Bowman IA; Lam ET; Abuqayas B; Bilen MA; Varkaris A; Zakharia Y; Harrison MR; Mortazavi A; Barthélémy P; Agarwal N; McKay RR; Brastianos PK; Krajewski KM; Albigès L; Harshman LC; Choueiri TK
    JAMA Oncol; 2021 Dec; 7(12):1815-1823. PubMed ID: 34673916
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Progression of Cabozantinib-Related Osteonecrosis Mimicking Metastases on Bone Scan.
    Xu G; Lu Y
    Clin Nucl Med; 2021 Jul; 46(7):592-594. PubMed ID: 33577198
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship Between Adverse Events and Progression-free Survival in Patients Receiving Cabozantinib for Previously Treated Metastatic Renal Cell Carcinoma.
    Sato R; Matsushita Y; Takemura A; Sugiyama M; Watanabe K; Watanabe H; Tamura K; Motoyama D; Nagata M; Otsuka A; Furuse H; Miyake H
    Anticancer Res; 2024 Feb; 44(2):781-786. PubMed ID: 38307571
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cabozantinib inhibits tumor growth and metastasis of a patient-derived xenograft model of papillary renal cell carcinoma with MET mutation.
    Zhao H; Nolley R; Chan AMW; Rankin EB; Peehl DM
    Cancer Biol Ther; 2017 Nov; 18(11):863-871. PubMed ID: 27715452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An In Vitro Analysis of TKI-Based Sequence Therapy in Renal Cell Carcinoma Cell Lines.
    Zaccagnino A; Vynnytska-Myronovska B; Stöckle M; Junker K
    Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982721
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.